Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novartis targets Xolair successor in buyout of startup Excellergy. Novartis will acquire Excellergy, a young allergy drugmaker, to gain access to an…
With its blockbuster drug Xolair set to face biosimilar competition, Novartis said it will pay up to $2 billion in upfront payments to acquire Excellergy and…
Novartis to acquire Excellergy for $2bn upfront. Excellergy's lead programme Exl-111 is being evaluated in the Phase 1 DISARM trial, a randomized,…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Novartis agreed to acquire privately held Excellergy for up to $2B in combined upfront and milestones, adding next-generation anti-IgE antibody Exl-111 (Phase 1 DISARM trial) to strengthen its allergy/immunology franchise beyond Xolair. The asset is designed to offer faster, deeper IgE pathway suppression across multiple IgE-driven conditions. Expected close H2 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Excellergy, Inc. (this deal) | 2026 | $2.0B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2026 deals · Novartis AG deals · Immunology deals